Trial Profile
A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- 31 Aug 2020 Status changed from recruiting to completed.
- 08 Mar 2012 New trial record